The company is trying to find a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.They looked promising, but somehow it didn't work out too plan. The share price has fallen close to 99 …
Humanigen. The maker of Lenzilumab still hopeful for future . Investors not so much.But Covid is making a comeback…
GLOBAL RISK FUND 